Evaluation of serotypes 5 and 8 capsular polysaccharides in protection against Staphylococcus aureus in murine models of infection

Human Vaccines and Immunotherapeutics

Volumn 13, Issue 7, 2017, Pages 1609-1614

  Cheng, Brian L ^a   Nielsen, Travis B ^b   Pantapalangkoor, Paul ^b   Zhao, Fan ^a   Lee, Jean C ^c   Montgomery, Christopher P ^a   Luna, Brian ^b   Spellberg, Brad ^b   Daum, Robert S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Capsular polysaccharides; Staphylococcus aureus; vaccine

Indexed keywords

POLYSACCHARIDE; BACTERIAL POLYSACCHARIDE; BACTERIAL PROTEIN; BACTERIUM ANTIBODY; CRM197 (NON-TOXIC VARIANT OF DIPHTHERIA TOXIN); IMMUNOLOGICAL ADJUVANT; STAPHYLOCOCCUS VACCINE; VACCINE;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BACTEREMIA; BACTERIAL LOAD; BLOOD CULTURE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOGENICITY; MORTALITY RATE; MOUSE; NONHUMAN; SEPSIS; SEROTYPE; SKIN INFECTION; SKIN NECROSIS; STAPHYLOCOCCUS INFECTION; VEIN PUNCTURE; ANIMAL; BAGG ALBINO MOUSE; BLOOD; DISEASE MODEL; HUMAN; IMMUNOLOGY; MICROBIOLOGY; STAPHYLOCOCCAL SKIN INFECTION; STAPHYLOCOCCUS AUREUS; SURVIVAL ANALYSIS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; BACTEREMIA; BACTERIAL LOAD; BACTERIAL PROTEINS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MICE, INBRED BALB C; POLYSACCHARIDES, BACTERIAL; SEROGROUP; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCAL VACCINES; STAPHYLOCOCCUS AUREUS; SURVIVAL ANALYSIS; VACCINES, CONJUGATE;

EID: 85018820396     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2017.1304334     Document Type: Article

References (44)

1. Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, Carey RB, Talan DA, EMERGEncy ID Net Study Group. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006; 355:666-74; PMID:16914702; https://doi.org/10.1056/NEJMoa055356
2. David MZ, Medvedev S, Hohmann SF, Ewigman B, Daum RS. Increasing burden of methicillin-resistant Staphylococcus aureus hospitalizations at US academic medical centers, 2003-2008. Infect Control Hosp Epidemiol 2012; 33:782-9; PMID:22759545; https://doi.org/10.1086/666640
3. Herold BC, Immergluck LC, Maranan MC, Lauderdale DS, Gaskin RE, Boyle-Vavra S, Leitch CD, Daum RS. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 1998; 279:593-8; PMID:9486753; https://doi.org/10.1001/jama.279.8.593
4. Naimi TS, LeDell KH, Como-Sabetti K, Borchardt SM, Boxrud DJ, Etienne J, Johnson SK, Vandenesch F, Fridkin S, O'Boyle C, et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003; 290:2976-84; PMID:14665659; https://doi.org/10.1001/jama.290.22.2976
5. Chambers HF, Deleo FR. Waves of resistance:Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol 2009; 7:629-41; PMID:19680247; https://doi.org/10.1038/nrmicro2200
6. Trotter CL, McVernon J, Ramsay ME, Whitney CG, Mulholland EK, Goldblatt D, Hombach J, Kieny MP, SAGE subgroup. Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae. Vaccine 2008; 26:4434-45; PMID:18617296; https://doi.org/10.1016/j.vaccine.2008.05.073
7. Cocchiaro JL, Gomez MI, Risley A, Solinga R, Sordelli DO, Lee JC. Molecular characterization of the capsule locus from non-typeable Staphylococcus aureus. Mol Microbiol 2006; 59:948-60; PMID:16420363; https://doi.org/10.1111/j.1365-2958.2005.04978.x
8. Arbeit RD, Karakawa WW, Vann WF, Robbins JB. Predominance of two newly described capsular polysaccharide types among clinical isolates of Staphylococcus aureus. Diagn Microbiol Infect Dis 1984; 2:85-91; PMID:6232086; https://doi.org/10.1016/0732-8893(84)90002-6
9. Hochkeppel HK, Braun DG, Vischer W, Imm A, Sutter S, Staeubli U, Guggenheim R, Kaplan EL, Boutonnier A, Fournier JM. Serotyping and electron microscopy studies of Staphylococcus aureus clinical isolates with monoclonal antibodies to capsular polysaccharide types 5 and 8. J Clin Microbiol 1987; 25:526-30; PMID:2437148
10. O'Riordan K, Lee JC. Staphylococcus aureus capsular polysaccharides. Clin Microbiol Rev 2004; 17:218-34; PMID:14726462; https://doi.org/10.1128/CMR.17.1.218-234.2004
11. Thakker M, Park JS, Carey V, Lee JC. Staphylococcus aureus serotype 5 capsular polysaccharide is antiphagocytic and enhances bacterial virulence in a murine bacteremia model. Infect Immun 1998; 66:5183-9; PMID:9784520
12. Watts A, Ke D, Wang Q, Pillay A, Nicholson-Weller A, Lee JC. Staphylococcus aureus strains that express serotype 5 or serotype 8 capsular polysaccharides differ in virulence. Infect Immun 2005; 73:3502-11; PMID:15908379; https://doi.org/10.1128/IAI.73.6.3502-3511.2005
13. Nanra JS, Buitrago SM, Crawford S, Ng J, Fink PS, Hawkins J, Scully IL, McNeil LK, Aste-Amézaga JM, Cooper D. Capsular polysaccharides are an important immune evasion mechanism for Staphylococcus aureus. Hum Vaccin Immunother 2013; 9:480-7; PMID:23249887; https://doi.org/10.4161/hv.23223
14. Wacker M, Wang L, Kowarik M, Dowd M, Lipowsky G, Faridmoayer A, Shields K, Park S, Alaimo C, Kelley KA, et al. Prevention of Staphylococcus aureus infections by glycoprotein vaccines synthesized in Escherichia coli. J Infect Dis 2014; 209:1551-61; PMID:24308931; https://doi.org/10.1093/infdis/jit800
15. Park S, Gerber S, Lee JC. Antibodies to Staphylococcus aureus serotype 8 capsular polysaccharide react with and protect against serotype 5 and 8 isolates. Infect Immun 2014; 82:5049-55; PMID:25245803; https://doi.org/10.1128/IAI.02373-14
16. McLoughlin RM, Solinga RM, Rich J, Zaleski KJ, Cocchiaro JL, Risley A, Tzianabos AO, Lee JC. CD4+ T cells and CXC chemokines modulate the pathogenesis of Staphylococcus aureus wound infections. Proc Natl Acad Sci U S A 2006; 103:10408-13; PMID:16801559; https://doi.org/10.1073/pnas.0508961103
17. Nilsson IM, Lee JC, Bremell T, Ryden C, Tarkowski A. The role of staphylococcal polysaccharide microcapsule expression in septicemia and septic arthritis. Infect Immun 1997; 65:4216-21; PMID:9317029
18. Portoles M, Kiser KB, Bhasin N, Chan KHN, Lee JC. Staphylococcus aureus Cap5O has UDP-ManNAc dehydrogenase activity and is essential for capsule expression. Infect Immun 2001; 69:917-23; PMID:11159986; https://doi.org/10.1128/IAI.69.2.917-923.2001
19. Spellberg B, Daum R. A new view on development of a Staphylococcus aureus vaccine:Insights from mice and men. Hum Vaccin 2010; 6:857-9; PMID:20930569; https://doi.org/10.4161/hv.6.10.12469
20. Daum RS, Spellberg B. Progress toward a Staphylococcus aureus vaccine. Clin Infect Dis 2012; 54:560-7; PMID:22186773; https://doi.org/10.1093/cid/cir828
21. Spellberg B, Daum R. Development of a vaccine against Staphylococcus aureus. Semin Immunopathol 2012; 34:335-48; PMID:22080194; https://doi.org/10.1007/s00281-011-0293-5
22. Sutter DE, Summers AM, Keys CE, Taylor KL, Frasch CE, Braun LE, Fattom AI, Bash MC. Capsular serotype of Staphylococcus aureus in the era of community-acquired MRSA. FEMS Immunol Med Microbiol 2011; 63:16-24; PMID:21631600; https://doi.org/10.1111/j.1574-695X.2011.00822.x
23. Montgomery CP, Boyle-Vavra S, Adem PV, Lee JC, Husain AN, Clasen J, Daum RS. Comparison of virulence in community-associated methicillin-resistant Staphylococcus aureus pulsotypes USA300 and USA400 in a rat model of pneumonia. J Infect Dis 2008; 198:561-70; PMID:18598194; https://doi.org/10.1086/590157
24. Fattom A, Schneerson R, Watson DC, Karakawa WW, Fitzgerald D, Pastan I, Li X, Shiloach J, Bryla DA, Robbins JB. Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A. Infect Immun 1993; 61:1023-32; PMID:8432585
25. Fattom A, Schneerson R, Szu SC, Vann WF, Shiloach J, Karakawa WW, Robbins JB. Synthesis and immunologic properties in mice of vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides conjugated to Pseudomonas aeruginosa exotoxin A. Infect Immun 1990; 58:2367-74; PMID:2114365
26. Fattom AI, Sarwar J, Ortiz A, Naso R. A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge. Infect Immun 1996; 64:1659-65; PMID:8613375
27. Lee JC, Park JS, Shepherd SE, Carey V, Fattom A. Protective efficacy of antibodies to the Staphylococcus aureus type 5 capsular polysaccharide in a modified model of endocarditis in rats. Infect Immun 1997; 65:4146-51; PMID:9317020
28. Lattar SM, Noto Llana M, Denoel P, Germain S, Buzzola FR, Lee JC, Sordelli DO. Protein antigens increase the protective efficacy of a capsule-based vaccine against Staphylococcus aureus in a rat model of osteomyelitis. Infect Immun 2014; 82:83-91; PMID:24126523; https://doi.org/10.1128/IAI.01050-13
29. Skurnik D, Merighi M, Grout M, Gadjeva M, Maira-Litran T, Ericsson M, Goldmann DA, Huang SS, Datta R, Lee JC, et al. Animal and human antibodies to distinct Staphylococcus aureus antigens mutually neutralize opsonic killing and protection in mice. J Clin Invest 2010; 120:3220-33; PMID:20739753; https://doi.org/10.1172/JCI42748
30. Tuchscherr LP, Buzzola FR, Alvarez LP, Lee JC, Sordelli DO. Antibodies to capsular polysaccharide and clumping factor A prevent mastitis and the emergence of unencapsulated and small-colony variants of Staphylococcus aureus in mice. Infect Immun 2008; 76:5738-44; PMID:18809660; https://doi.org/10.1128/IAI.00874-08
31. Pozzi C, Wilk K, Lee JC, Gening M, Nifantiev N, Pier GB. Opsonic and protective properties of antibodies raised to conjugate vaccines targeting six Staphylococcus aureus antigens. PLoS One 2012; 7:e46648; PMID:23077517; https://doi.org/10.1371/journal.pone.0046648
32. Wacker M, Wang L, Kowarik M, Dowd M, Lipowsky G, Faridmoayer A, Shields K, Park S, Alaimo C, Kelley KA, et al. Prevention of Staphylococcus aureus infections by glycoprotein vaccines synthesized in Escherichia coli. J Infect Dis 2014; 209:1551-61; PMID:24308931; https://doi.org/10.1093/infdis/jit800
33. Thakker M, Park JS, Carey V, Lee JC. Staphylococcus aureus serotype 5 capsular polysaccharide is antiphagocytic and enhances bacterial virulence in a murine bacteremia model. Infect Immun 1998; 66:5183-9; PMID:9784520
34. Boyle-Vavra S, Li X, Alam MT, Read TD, Sieth J, Cywes-Bentley C, Dobbins G, David MZ, Kumar N, Eells SJ, et al. USA300 and USA500 clonal lineages of Staphylococcus aureus do not produce a capsular polysaccharide due to conserved mutations in the cap5 locus. MBio 2015; 6:02585-14; PMID:25852165; https://doi.org/10.1128/mBio.02585-14
35. Shinefield H, Black S, Fattom A, Horwith G, Rasgon S, Ordonez J, Yeoh H, Law D, Robbins JB, Schneerson R, et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med 2002; 346:491-6; PMID:11844850; https://doi.org/10.1056/NEJMoa011297
36. Fattom A, Matalon A, Buerkert J, Taylor K, Damaso S, Boutriau D. Efficacy profile of a bivalent Staphylococcus aureus glycoconjugated vaccine in adults on hemodialysis:Phase III randomized study. Hum Vaccin Immunother 2015; 11:632-41; PMID:25483694; https://doi.org/10.4161/hv.34414
37. Duthie ES, Lorenz LL. Staphylococcal coagulase; mode of action and antigenicity. J Gen Microbiol 1952; 6:95-107; PMID:14927856; https://doi.org/10.1099/00221287-6-1-2-95
38. Linde H, Wagenlehner F, Strommenger B, Drubel I, Tanzer J, Reischl U, Raab U, Holler C, Naber KG, Witte W, et al. Healthcare-associated outbreaks and community-acquired infections due to MRSA carrying the Panton-Valentine leucocidin gene in southeastern Germany. Eur J Clin Microbiol Infect Dis 2005; 24:419-22; PMID:15937659; https://doi.org/10.1007/s10096-005-1341-7
39. Stegger M, Price LB, Larsen AR, Gillece JD, Waters AE, Skov R, Andersen PS. Genome sequence of Staphylococcus aureus strain 11819-97, an ST80-IV European community-acquired methicillin-resistant isolate. J Bacteriol 2012; 194:1625-6; PMID:22374956; https://doi.org/10.1128/JB.06653-11
40. Montgomery CP, Daniels M, Zhao F, Alegre ML, Chong AS, Daum RS. Protective immunity against recurrent Staphylococcus aureus skin infection requires antibody and interleukin-17A. Infect Immun 2014; 82:2125-34; PMID:24614654; https://doi.org/10.1128/IAI.01491-14
41. Spellberg B, Ibrahim AS, Yeaman MR, Lin L, Fu Y, Avanesian V, Bayer AS, Filler SG, Lipke P, Otoo H, et al. The antifungal vaccine derived from the recombinant N terminus of Als3p protects mice against the bacterium Staphylococcus aureus. Infect Immun 2008; 76:4574-80; PMID:18644876; https://doi.org/10.1128/IAI.00700-08
42. Tzianabos AO, Wang JY, Lee JC. Structural rationale for the modulation of abscess formation by Staphylococcus aureus capsular polysaccharides. Proc Natl Acad Sci USA 2001; 98:9365-70; PMID:11470905; https://doi.org/10.1073/pnas.161175598
43. Lee JC, Takeda S, Livolsi PJ, Paoletti LC. Effects of in vitro and in vivo growth conditions on expression of type 8 capsular polysaccharide by Staphylococcus aureus. Infect Immun 1993; 61:1853-8; PMID:8478074
44. Gray BM. ELISA methodology for polysaccharide antigens:Protein coupling of polysaccharides for adsorption to plastic tubes. J Immunol Methods 1979; 28:187-92; PMID:38284; https://doi.org/10.1016/0022-1759(79)90340-5